Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to ...

It seems to be holding off on price adjustments demanded by President Trump.

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

Tonix Pharmaceuticals was founded in 2010 to develop and bring to market a drug for fibromyalgia. | Tonix Pharmaceuticals was ...

Gain insight on Eli Lilly, WELL Health Technologies and more in the latest Market Talks covering the Health Care sector.

From geopolitics to climate, tech to social change, News18 World live blog delivers real-time updates on what is the latest ...